@rboussageon.bsky.social
FLX was not superior to PBO.....
November 22, 2025 at 11:14 AM
FLX was not superior to PBO.....
Reposted
@ioanaacristea.bsky.social
@ploederl.bsky.social
@floriannaudet.bsky.social
No difference between fluoxetine and placebo in a powerful double-blind trial.
Combo effect linked to lack of insu?
@ploederl.bsky.social
@floriannaudet.bsky.social
No difference between fluoxetine and placebo in a powerful double-blind trial.
Combo effect linked to lack of insu?
October 9, 2025 at 1:36 PM
@ioanaacristea.bsky.social
@ploederl.bsky.social
@floriannaudet.bsky.social
No difference between fluoxetine and placebo in a powerful double-blind trial.
Combo effect linked to lack of insu?
@ploederl.bsky.social
@floriannaudet.bsky.social
No difference between fluoxetine and placebo in a powerful double-blind trial.
Combo effect linked to lack of insu?
REB: meta analysis of low-risk-of-bias trials and consideration of the confirmatory nature of trials
October 8, 2025 at 8:57 PM
REB: meta analysis of low-risk-of-bias trials and consideration of the confirmatory nature of trials
Or precautionary principle ...
Or less is better...
Or less is better...
October 8, 2025 at 5:59 AM
Or precautionary principle ...
Or less is better...
Or less is better...
Reposted
17/ Therefore, we dug deeper into the two Lancet NMAs and we indeed could explain the discrepancy after isolating a potential zombie trial. But more later, when this will be published, and we experienced the 4th rejection already (preprint here www.medrxiv.org/content/10.1...)
A Re-Appraisal of Three Network Meta-Analyses to Explain the Discrepancy in Findings for the Efficacy of Fluoxetine for the Treatment of Depression in Children and Adolescents
Objective To explain discrepant findings for fluoxetine’s efficacy in three influential network meta-analyses (NMAs) of treatments for pediatric depression, which led to conflicting clinical recommend...
www.medrxiv.org
September 26, 2025 at 5:00 AM
17/ Therefore, we dug deeper into the two Lancet NMAs and we indeed could explain the discrepancy after isolating a potential zombie trial. But more later, when this will be published, and we experienced the 4th rejection already (preprint here www.medrxiv.org/content/10.1...)
Yes, because we must first define what constitutes evidence....!
You should conduct an analysis with REB.😉
You should conduct an analysis with REB.😉
October 7, 2025 at 7:16 PM
Yes, because we must first define what constitutes evidence....!
You should conduct an analysis with REB.😉
You should conduct an analysis with REB.😉
Absence of evidence is not evidence of absence...😆
September 30, 2025 at 7:29 PM
Absence of evidence is not evidence of absence...😆